SCHEMBL1133192

SCHEMBL1133192

COc1ccccc1CN(CCN)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.55
BCHE P06276 3/20 0.55
TAAR1 Q96RJ0 1/20 0.54
CHRM2 P08172 6/20 0.50
AOC3 Q16853 1/20 0.49
IDO1 P14902 2/20 0.46
CHRM4 P08173 3/20 0.45
CHRM5 P08912 3/20 0.45
CHRM1 P11229 3/20 0.45
CHRM3 P20309 3/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.43
CRHBP P24387 1/20 0.43
KMT2A Q03164 1/20 0.43
CRHR2 Q13324 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26239757 0.84 BCHE (0.55) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL27909715 0.81 TAAR1 (0.59) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL7416019 0.80 CHRM2 (0.71) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL8590841 0.78 TAAR1 (0.55) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL4367373 0.77 ACHE (0.65) ACHEBCHETAAR1MAOB
SCHEMBL12088736 0.76 CHRM2 (0.56) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL4372177 0.74 CARM1 (0.58) TAAR1CHRM2AOC3CHRM1CHRM3
SCHEMBL8590941 0.74 AOC3 (0.52) ACHEBCHETAAR1CHRM2AOC3
SCHEMBL1132754 0.73 TAAR1 (0.41) ACHETAAR1AOC3IDO1ALDH1A1
SCHEMBL334999 0.73 TAAR1 (0.41) ACHETAAR1AOC3IDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 ACHE 1195/4885BCHE 1464/4885TAAR1 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.